Peptech name change to Arana Therapeutics
Peptech has announced an official name change to Arana Therapeutics. The company’s ASX code will change to AAH this week and its code on the London Stock Exchange has been changed to AAHx.
Arana Therapeutics, created by the merger of Peptech and EvoGenix in August 2007, is focused on developing antibody/protein-based new generation products and platforms for the treatment of inflammatory diseases and cancer.
“This final step in the merger of Peptech and EvoGenix creates a true global player in the antibody therapeutics sector,” said Robin Beaumont, chairman of Arana Therapeutics.
“As well as critical mass, Arana Therapeutics has the right mix of people, skills, technologies and, most importantly, financial backing to achieve international recognition. Our key focus now is to rapidly develop our exciting product pipeline.”
QIMR Berghofer signs strategic partnership with Nakanoshima Qross
QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...
Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director
Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
